1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

13 Jun 2024
Admin
News Article

Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb

Overview

Evotec SE, a life science company, announced that the company has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb triggering a research payment of US$ 20 million to Evotec. A target-based programme progresses into late pre-clinical development, further contributing to the fast-growing and promising pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.

About This Collaboration

Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases.
Currently approved drugs mainly offer short-term management of the patients’ symptoms and there is a significant unmet medical need for therapeutic modalities that slow down or prevent disease progression.

Studies for EVT8683

A first programme, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021 as BMS-986419.
Following a successful phase I study Bristol Myers Squibb announced that a phase II study for BMS-986419 is scheduled to commence in 2024.
In March 2023, Bristol Myers Squibb and Evotec extended and expanded this partnership for an additional 8 years.

Words From CSO: Evotec

Dr Cord Dohrmann, chief scientific officer of Evotec, said: “We are excited to further expand our pipeline with another high-potential programme progressing into late pre-clinical development, demonstrating the exceptional productivity of our neuroscience partnership with Bristol Myers Squibb and our shared commitment to innovation and patient care. Together with Bristol Myers Squibb we have been able to advance a growing portfolio of programmes to critical inflection points, bringing us closer to our joint goal of delivering new therapeutic options for patients suffering from devastating neurological disorders.”

Evotec

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!